When four executives of a medical-device company called Synthes went to jail for illegally marketing a bone cement—five patients had died after it was injected into their spines—Mina Kimes knew there had to be a compelling saga behind a case that had generated little coverage beyond local news articles. So she began digging, first with FOIA requests for never-before-published government documents, and then assembling hundreds of pages of court transcripts and internal company e-mails and reports. She used that foundation to begin the harder challenge: persuading Synthes employees, many of them terrified by the criminal case and the company's intimidating chairman, to talk to her. With six months of grueling, old-fashioned reporting, Kimes succeeded, and “Bad to the Bone” is the masterful result. Not only did she persuade more than 20 current and former company employees to speak, but she also revealed a story whose disturbing breadth far exceeded the case presented in court. Her tour de force reporting raises profound new questions about the culpability of a key figure who wasn't charged: Hansjörg Wyss, the reclusive and controlling Swiss founder and chairman—one of the richest people in the world—who made crucial decisions about how to sell the bone cement. This is a classic tale of corporate malfeasance: Warned by the government not to sell its bone cement for use in the spine, Synthes ignored the admonition despite clear evidence of lethal danger—a pig had died within seconds when the cement was tested on it—and encouraged surgeons to use the cement on people, five of whom died soon afterward. But “Bad to the Bone” isn't just an exposé. It opens a window into a broader issue: how the medical system actually runs. Readers see how salespeople with no medical training advise surgeons—inside the OR during operations—on how to use their devices. They experience the tale of one surgeon who continues using the cement even after two of his patients died. Oh, and what sort of justice does Synthes itself receive? Wyss sells it, for $20 billion, to health care giant Johnson & Johnson, which praises Synthes's “culture” and “values.” Corporate crime. Death on the operating room table. Secret e-mails. Surgeons on the edge. An imperious multibillionaire CEO. It's a mesmerizing article, and Kimes's reporting takes readers on a deeply unsettling journey that ensures they'll never look at the medical system the same way again.